Please ensure Javascript is enabled for purposes of website accessibility Jamie Ross, CFA - Janus Henderson Investors - Europe PA Sweden
For financial professionals in Sweden

Jamie Ross, CFA

Portfolio Manager | Deputy Portfolio Manager – Bankers Investment Trust
Jamie Ross | Janus Henderson Investors

Jamie Ross is a Portfolio Manager on the European Equities Team at Janus Henderson Investors, a position he has held since 2016. He was appointed as a joint Portfolio Manager for a European investment trust in 2018 and became sole manager in 2019. Prior to this, he was a portfolio manager on the UK Equities Team, where he co-managed a UK equities pooled fund. Before that, he was an assistant portfolio manager on the Pan European Equities Team. He started his career with Henderson in 2007.

Jamie graduated with a BA degree (Hons) in economics from Durham University. He holds the Chartered Financial Analyst designation and has 17 years of financial industry experience.

Articles Written

Quick view: French election poses questions for the EU as Le Pen falls short
Timely & Topical

Quick view: French election poses questions for the EU as Le Pen falls short

With the potential of a far-right government in France removed, talks now begin on the balance of power in a potential coalition government – and what this means for the EU.

European espresso: Initial French election results see a small bounce for risk assets
Timely & Topical

European espresso: Initial French election results see a small bounce for risk assets

The French parliamentary elections are a potential risk event for European equities, but what did the results of the first round of voting tell us?

European espresso:  Growth trends in skincare and fragrances
Timely & Topical

European espresso: Growth trends in skincare and fragrances

Can skincare and fragrances buck the trend within European consumer staples?

European espresso: Are obesity drugs a game changer for European pharmas?
Timely & Topical

European espresso: Are obesity drugs a game changer for European pharmas?

Just how significant could a breakthrough in obesity treatment be, in terms of European equity markets?